Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes

Cancer Cell

Volumn 6, Issue 1, 2004, Pages 7-10

  Brugarolas, James ^a   Kaelin Jr , William G ^a  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1; IMMUNOSUPPRESSIVE AGENT; PROTEIN SERINE THREONINE KINASE; RAPAMYCIN; TUBERIN; TUMOR SUPPRESSOR PROTEIN; VASCULOTROPIN;

CANCER INHIBITION; CONGENITAL TUMOR; GENE MUTATION; HUMAN; NONHUMAN; PEUTZ JEGHERS SYNDROME; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SHORT SURVEY;

EID: 3142587052     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2004.06.020     Document Type: Review

References (48)

1. Anand N., Murthy S., Amann G., Wernick M., Porter L.A., Cukier I.H., Collins C., Gray J.W., Diebold J., Demetrick D.J., Lee J.M. Protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer. Nat. Genet. 31:2002;301-305
2. Avdulov S., Li S., Michalek V., Burrichter D., Peterson M., Perlman D.M., Manivel J.C., Sonenberg N., Yee D., Bitterman P.B., Polunovsky V.A. Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell. 5:2004;553-563
3. Bardeesy N., Sinha M., Hezel A.F., Signoretti S., Hathaway N.A., Sharpless N.E., Loda M., Carrasco D.R., DePinho R.A. Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation. Nature. 419:2002;162-167
4. Boudeau J., Sapkota G., Alessi D.R. LKB1, a protein kinase regulating cell proliferation and polarity. FEBS Lett. 546:2003;159-165
5. Brugarolas J., Vazquez F., Reddy A., Sellers W.R., Kaelin W.G. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell. 4:2003;147-156
6. Cantley L.C. The phosphoinositide 3-kinase pathway. Science. 296:2002;1655-1657
7. Carling D. The AMP-activated protein kinase cascade-a unifying system for energy control. Trends Biochem. Sci. 29:2004;18-24
8. Cheadle J.P., Reeve M.P., Sampson J.R., Kwiatkowski D.J. Molecular genetic advances in tuberous sclerosis. Hum. Genet. 107:2000;97-114
9. Corrandeti M.N., Inoki K., Bardeesy N., DePinho R.A., Guan K.L. Regulation of the TSC pathway by LKB1. evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeguers syndrome Genes Dev. in press:2004
10. Dang C.V., Semenza G.L. Oncogenic alterations of metabolism. Trends Biochem. Sci. 24:1999;68-72
11. De Benedetti A., Graff J.R. eIF-4E expression and its role in malignancies and metastases. Oncogene. 23:2004;3189-3199
12. El-Hashemite N., Walker V., Zhang H., Kwiatkowski D.J. Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin. Cancer Res. 63:2003;5173-5177. a
13. El-Hashemite N., Zhang H., Henske E.P., Kwiatkowski D.J. Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma. Lancet. 361:2003;1348-1349. b
14. Eng C. Pten. One gene, many syndromes Hum. Mutat. 22:2003;183-198
15. Fingar D.C., Blenis J. Target of rapamycin (TOR). An integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression Oncogene. 23:2004;3151-3171
16. Hawley S.A., Boudeau J., Reid J.L., Mustard K.J., Udd L., Makela T.P., Alessi D.R., Hardie D.G. Complexes between the LKB1 tumor suppressor, STRADα/β and MO25α/β are upstream kinases in the AMP-activated protein kinase cascade. J. Biol. 2:2003;28
17. Hemminki A., Markie D., Tomlinson I., Avizienyte E., Roth S., Loukola A., Bignell G., Warren W., Aminoff M., Hoglund P., et al. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature. 391:1998;184-187
18. Holland E.C., Sonenberg N., Pandolfi P.P., Thomas G. Signaling control of mRNA translation in cancer pathogenesis. Oncogene. 23:2004;3138-3144
19. Hudson C.C., Liu M., Chiang G.G., Otterness D.M., Loomis D.C., Kaper F., Giaccia A.J., Abraham R.T. Regulation of hypoxia-inducible factor 1α expression and function by the mammalian target of rapamycin. Mol. Cell. Biol. 22:2002;7004-7014
20. Inoki K., Li Y., Zhu T., Wu J., Guan K.L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 4:2002;648-657
21. Inoki K., Zhu T., Guan K.L. TSC2 mediates cellular energy response to control cell growth and survival. Cell. 115:2003;577-590
22. Jenne D.E., Reimann H., Nezu J., Friedel W., Loff S., Jeschke R., Muller O., Back W., Zimmer M. Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat. Genet. 18:1998;38-43
23. Jiang B.H., Jiang G., Zheng J.Z., Lu Z., Hunter T., Vogt P.K. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ. 12:2001;363-369
24. Kaelin W.G. Jr. How oxygen makes its presence felt. Genes Dev. 16:2002;1441-1445
25. Kaelin, W.G., Jr. (2004). Gleevec: Prototype or outlier? Sci STKE 2004, pe12.
26. Kondo K., Klco J., Nakamura E., Lechpammer M., Kaelin W.G. Jr. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell. 1:2002;237-246
27. Kondo, K., Kim, W.Y., Lechpammer, M., and Kaelin, W.G., Jr. (2003). Inhibition of HIF2α is sufficient to suppress pVHL-defective tumor growth
28. Liu M.Y., Poellinger L., Walker C.L. Up-regulation of hypoxia-inducible factor 2α in renal cell carcinoma associated with loss of Tsc-2 tumor suppressor gene. Cancer Res. 63:2003;2675-2680
29. Lizcano J.M., Goransson O., Toth R., Deak M., Morrice N.A., Boudeau J., Hawley S.A., Udd L., Makela T.P., Hardie D.G., Alessi D.R. LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J. 23:2004;833-843
30. Majumder P.K., Febbo P.G., Bikoff R., Berger R., Xue Q., McMahon L.M., Manola J., Brugarolas J., McDonnell T.J., Golub T.R., et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat. Med. 10:2004;594-601
31. Mamane Y., Petroulaki E., Rong L., Yoshida K., Ler L.W., Sonenberg N. eIF4E - from translation to transformation. Oncogene. 23:2004;3172-3179
32. Manning B.D., Tee A.R., Logsdon M.N., Blenis J., Cantley L.C. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol. Cell. 10:2002;151-162
33. Maranchie J.K., Vasselli J.R., Riss J., Bonifacino J.S., Linehan W.M., Klausner R.D. The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell. 1:2002;247-255
34. Mazure N.M., Chen E.Y., Laderoute K.R., Giaccia A.J. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood. 90:1997;3322-3331
35. Nguyen-Vu P.A., Fackler I., Rust A., DeClue J.E., Sander C.A., Volkenandt M., Flaig M., Yeung R.S., Wienecke R. Loss of tuberin, the tuberous-sclerosis- complex-2 gene product is associated with angiogenesis. J. Cutan. Pathol. 28:2001;470-475
36. Potter C.J., Pedraza L.G., Xu T. Akt regulates growth by directly phosphorylating Tsc2. Nat. Cell Biol. 4:2002;658-665
37. Ruggero D., Montanaro L., Ma L., Xu W., Londei P., Cordon-Cardo C., Pandolfi P.P. The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat. Med. 10:2004;484-486
38. Sawyers C.L. Will mTOR inhibitors make it as cancer drugs? Cancer Cell. 4:2003;343-348
39. Shaw R.J., Bardeesy N., Manning B.D., Lopez L., Kostmatka M., DePinho R.A., Cantley L.C. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell. 6:2004;. a this issue
40. Shaw R.J., Kosmatka M., Bardeesy N., Hurley R.L., Witters L.A., DePinho R.A., Cantley L.C. Inaugural Article. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress Proc. Natl. Acad. Sci. USA. 101:2004;3329-3335. b
41. Weinstein I.B. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science. 297:2002;63-64
42. Wendel H.G., De Stanchina E., Fridman J.S., Malina A., Ray S., Kogan S., Cordon-Cardo C., Pelletier J., Lowe S.W. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature. 428:2004;332-337
43. Wirtzfeld D.A., Petrelli N.J., Rodriguez-Bigas M.A. Hamartomatous polyposis syndromes. Molecular genetics, neoplastic risk, and surveillance recommendations Ann. Surg. Oncol. 8:2001;319-327
44. Woods A., Johnstone S.R., Dickerson K., Leiper F.C., Fryer L.G., Neumann D., Schlattner U., Wallimann T., Carlson M., Carling D. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr. Biol. 13:2003;2004-2008
45. Ylikorkala A., Rossi D.J., Korsisaari N., Luukko K., Alitalo K., Henkemeyer M., Makela T.P. Vascular abnormalities and deregulation of VEGF in Lkb1-deficient mice. Science. 293:2001;1323-1326
46. Zhong H., Chiles K., Feldser D., Laughner E., Hanrahan C., Georgescu M.M., Simons J.W., Semenza G.L. Modulation of hypoxia-inducible factor 1α expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells. Implications for tumor angiogenesis and therapeutics Cancer Res. 60:2000;1541-1545
47. Zimmer M., Doucette D., Siddiqui N., Iliopoulos O. Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors. Mol. Cancer Res. 2:2004;89-95
48. Zundel W., Schindler C., Haas-Kogan D., Koong A., Kaper F., Chen E., Gottschalk A.R., Ryan H.E., Johnson R.S., Jefferson A.B., et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev. 14:2000;391-396